Especially, our antibodies likely outperform current Fc-deficient checkpoint inhibitors in cancers such as B cell lymphoma and myeloid leukemia, where the cancer cells express Fcγ receptors, and Fc-competent multispecific checkpoint inhibitors can promote cancer cell-T cell interaction through both Ab-Ag binding and Fc-FcR binding. Here, RENBP is linked to B-cell non-Hodgkin lymphoma.